SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

SAN

81.96

+0.52%↑

UCB

250.8

-0.63%↓

SHL.DE

35.81

-1.59%↓

ARGX

603.6

+0.5%↑

VIE

31.98

-0.22%↓

Home・Akciju saraksts・Pharma Mar SA

P
Pharma Mar SA

Slēgts

88.25 -2

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

85.85

Max

88.95

Galvenie mērījumi
By Trading Economics
Ienākumi	64M 60M
Pārdošana	55M 90M
P/E Sektora vidējais	38.205 57.05
EPS	3.418
Peļņas marža	65.946
Darbinieki	505
EBITDA	44M 42M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+32.96% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 23. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-166M 1.3B
Iepriekšējā atvēršanas cena	90.25
Iepriekšējā slēgšanas cena	88.25

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

72.75 / 74.3 Atbalsts un pretestība

Pharma Mar SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. marts 17:33 UTC

Galvenie ziņu notikumi

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

2026. g. 27. marts 17:00 UTC

Galvenie ziņu notikumi

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

2026. g. 27. marts 16:03 UTC

Galvenie ziņu notikumi

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

2026. g. 27. marts 14:50 UTC

Galvenie tirgus virzītāji

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

2026. g. 27. marts 14:37 UTC

Iegādes, apvienošanās, pārņemšana

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

2026. g. 27. marts 14:29 UTC

Galvenie ziņu notikumi

EU Finance Ministers Tally Economic Hit of Iran War -- Update

2026. g. 27. marts 14:16 UTC

Galvenie ziņu notikumi

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

2026. g. 27. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 19:16 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

2026. g. 27. marts 19:07 UTC

Tirgus saruna

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

2026. g. 27. marts 19:04 UTC

Tirgus saruna

Gold Rises But Can't Finish the Week Positive -- Market Talk

2026. g. 27. marts 19:03 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 19:02 UTC

Tirgus saruna

Galvenie ziņu notikumi

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

2026. g. 27. marts 18:12 UTC

Tirgus saruna

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

2026. g. 27. marts 17:36 UTC

Galvenie ziņu notikumi

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

2026. g. 27. marts 17:34 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

2026. g. 27. marts 17:29 UTC

Tirgus saruna

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

2026. g. 27. marts 16:38 UTC

Tirgus saruna

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

2026. g. 27. marts 16:32 UTC

Tirgus saruna

Galvenie ziņu notikumi

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

2026. g. 27. marts 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. marts 15:43 UTC

Tirgus saruna

Galvenie ziņu notikumi

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 15:25 UTC

Tirgus saruna

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

2026. g. 27. marts 15:00 UTC

Galvenie ziņu notikumi

Fed's Barkin Says Iran War Raising Economic Uncertainty

2026. g. 27. marts 14:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

2026. g. 27. marts 14:26 UTC

Tirgus saruna

Galvenie ziņu notikumi

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

2026. g. 27. marts 14:14 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. marts 14:14 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Pharma Mar SA Prognoze

Cenas mērķis

By TipRanks

32.96% augšup

Prognoze 12 mēnešiem

Vidējais 120 EUR 32.96%

Augstākais 120 EUR

Zemākais 120 EUR

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pharma Mar SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pharma Mar SA — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

72.75 / 74.3Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

All events are bullish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.